Immunovant, Inc.
News
What the Options Market Tells Us About Immunovant
Benzinga Whales with a lot of money to spend have taken a noticeably bullish stance on Immunovant. Looking at options history for Immunovant IMVT we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with bullish expectations and 30% with bearish.\n more…
Immunovant (NASDAQ:IMVT) Rating Reiterated by Cantor Fitzgerald
Ticker Report Immunovant (NASDAQ:IMVT - Get Free Report)s stock had its "overweight" rating reaffirmed by research analysts at Cantor Fitzgerald in a research note issued to investors on Monday, Benzinga...\n more…
Stock Traders Buy High Volume of Immunovant Call Options (NASDAQ:IMVT)
Ticker Report Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) was the recipient of some unusual options trading activity on Monday. Investors purchased 4,328 call options on the company. This is an increase of...\n more…
Immunovant stock falls 8% amid Graves' disease program update
Seeking Alpha - Healthcare Immunovant stock falls 8% amid Graves' disease program update...\n more…
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Benzinga Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the end of 2024.\n more…